Home
Solution
Impact
Science
Publications
About
Team and Board
News and Events
All News
All Events
All Press Releases
Contact
unnamed
Home
News
Phase I Study Results of a Novel Immunomodulatory Peptide, TCP-25, for Treatment of Dystrophic Epidermolysis Bullosa
unnamed
